Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis

References

• Van der Koff P, Schalkwijk J. Psoriasis. In: Bolognia JL, Jorizzo JL, Rapini RP, et al. Dermatology. 2nd ed. Spain: Mosby Elsevier; 2008: 115–135.
   Google Scholar
• Andressen C, Henseler T. Inheritance of psoriasis: analysis of 2035 family histories. Hautarzt. 1982;33:214–217.
   PubMed Web of Science ®Google Scholar
• Kremers HM, McEvoy MT, Dann FJ, et al. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57:347–354.
   PubMed Web of Science ®Google Scholar
• Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;215:17–27.
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. Statistics. Available from: http://www.psoriasis.org/about/stats. Accessed December 21, 2013.
   Google Scholar
• Schon MP, Boehncke WH. Psoriasis. N Eng J Med. 2005;352:1899–1912.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(Suppl 2):ii30–ii36.
   Web of Science ®Google Scholar
• Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther. 2008;117:244–279.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Wozel G. Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics. 2009;3:303–318.
   PubMedGoogle Scholar
• Food and Drug Administration. Humira (adalimumab) [package insert]. US Govt Lic No 0043, Abbott Laboratories. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf. Accessed January 4, 2014.
   Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blinded, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled Phase III trial. J Am Acad Dermatol. 2008;58:106–115.
   PubMed Web of Science ®Google Scholar
• Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011;164:434–441.
   PubMed Web of Science ®Google Scholar
• Crowley J, Ortonne JP, Gu Y, et al. The efficacy of retreatment with adalimumab in moderate to severe psoriasis following treatment interruption after 33 weeks or >3 years of 40 mg every other week dosing. J Am Acad Dermatol. 2011;64:2 Suppl AB151.
   Web of Science ®Google Scholar
• Menter A, Gordon K, Leonardi C, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63:448–456.
   PubMed Web of Science ®Google Scholar
• Saurat J, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566.
   PubMed Web of Science ®Google Scholar
• Reich K, Signorovitch J, Ramakrishnan K, et al. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatement of moderate to severe psoriasis; comparison of adverse-event free response days in the CHAMPION trial. J Am Acad Dermatol. 2010;63:1011–1018.
   PubMed Web of Science ®Google Scholar
• Thaci D, Ortonne JP, Chimenti S, et al. A Phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol. 2010;163:402–411.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety, and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167:658–667.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Damn TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164:1091–1096.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nobeyama Y, Hayashi M, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40:1008–1013.
   PubMed Web of Science ®Google Scholar
• Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64:671–681.
   PubMed Web of Science ®Google Scholar
• Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2012;10:1079–1087.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Bartelds GM, Lems WF, et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther. 2010;12:217.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71:1914–1915.
   PubMed Web of Science ®Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Anti-drug antibodies in psoriasis: a systematic review. Br J Dermatol. Epub October 1, 2013.
   Google Scholar
• Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatolog. 2011;12:321–337.
   PubMed Web of Science ®Google Scholar
• Thaci D, Kerdel F, Wu J. Fourth-year interim safety and patient outcomes from ESPRIT, a 10-year postmarketing surveillance registry of adalimumab for moderate to severe psoriasis. Presented at: The 14th Annual Las Vegas Dermatology Seminar and presented at the 10th Annual SDEF Psoriasis Forum; October 31–November 2, 2013; Las Vegas, NV.
   Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18:341–350.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Menter A, Feldman S, et al. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008;6:75.
   PubMed Web of Science ®Google Scholar
• Stober BE, Sobell JM, Duffin KC, et al. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol. 2012;167(6):1374–1381.
   Web of Science ®Google Scholar